- List
- By Topic
- On Map
- Search Details

"Mantle cell lymphoma"
Need help? See RSS Feeds
Choose a feed type:

"Mantle cell lymphoma" (925 records)
Need help? See Downloading Content for Analysis
For Advanced Users: Full Study Record XML Download
101 | NCT01865110 | Recruiting | R-CHOP + R-HAD vs R-CHOP Followed by Maintenance Lenalidomide + Rituximab vs Rituximab for Older Patients With MCL |
|
|
Interventional | Phase 3 |
|
Other |
|
|
633 | All | 60 Years and older (Adult, Senior) | NCT01865110 | MCL R2 Elderly | November 2013 | June 2021 | March 2024 | May 30, 2013 | March 7, 2018 |
|
||
102 | NCT00730652 | Withdrawn | Study of MDX-1411 in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma |
|
|
Interventional | Phase 1 |
|
Industry |
|
|
34 | All | 18 Years and older (Adult, Senior) | NCT00730652 | MDX1411-02 | MDX1411-02 | May 2009 | December 2012 | March 2013 | August 8, 2008 | April 22, 2010 | ||
103 | NCT01073163 | Completed Has Results |
Study to Assess the Effect of Treatment With Bendamustine in Combination With Rituximab on QT Interval in Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) |
|
|
Interventional | Phase 3 |
|
Industry |
|
|
54 | All | 18 Years and older (Adult, Senior) | NCT01073163 | C18083/3070 | February 2010 | June 2012 | June 2012 | February 23, 2010 | April 24, 2014 | April 4, 2014 |
|
|
104 | NCT02354313 | Active, not recruiting | Phase III, Randomized Trial: Lenalidomide vs Observation After Induction With Rituximab Followed by Cht and ASCT in MCL Adult Patients |
|
|
Interventional | Phase 3 |
|
Other |
|
|
300 | All | 18 Years to 60 Years (Adult) | NCT02354313 | IIL-MCL0208 2009-012807-25 |
MCL0208 | May 2010 | December 2017 | January 2019 | February 3, 2015 | February 9, 2018 |
|
|
105 | NCT01933711 | Active, not recruiting | Rituximab Maintenance Therapy in Aggressive CD20 (Cluster of Differentiation Antigen 20) Positive Lymphoma and Mantle Cell Lymphoma |
|
|
Interventional | Phase 3 |
|
Other |
|
|
328 | All | 18 Years and older (Adult, Senior) | NCT01933711 | HD2002 | July 2002 | December 2016 | December 2018 | September 2, 2013 | May 13, 2016 |
|
||
106 | NCT02682641 | Recruiting | Ibrutinib in Combination With Rituximab in Patients With Indolent Clinical Forms of MCL |
|
|
Interventional | Phase 2 |
|
Other / Industry |
|
|
50 | All | 18 Years to 99 Years (Adult, Senior) | NCT02682641 | GELTAMO-IMCL-2015 2015-004158-17 |
May 2016 | January 2020 | January 2023 | February 15, 2016 | June 12, 2017 |
|
||
107 | NCT00877006 | Completed Has Results |
Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study |
|
|
Interventional | Phase 3 |
|
Industry |
|
|
447 | All | 18 Years and older (Adult, Senior) | NCT00877006 | C18083/3064/NL/MN | April 30, 2009 | March 31, 2012 | March 31, 2012 | April 7, 2009 | February 5, 2018 | April 28, 2014 |
|
|
108 | NCT01449344 | Active, not recruiting | Efficacy and Safety of R-HAD Alone or in Combination With Bortezomib in Patients With Relapsed or Refractory MCL |
|
|
Interventional | Phase 3 |
|
Other / Industry |
|
|
128 | All | 18 Years and older (Adult, Senior) | NCT01449344 | MCL2005-01 | (R-HAD) | May 9, 2009 | December 2018 | December 2018 | October 10, 2011 | March 7, 2017 |
|
|
109 | NCT02081937 | Recruiting | CART-19 Immunotherapy in Mantle Cell Lymphoma |
|
|
Interventional | Phase 1 Phase 2 |
|
Other |
|
|
2 | All | 50 Years to 80 Years (Adult, Senior) | NCT02081937 | CN301-XYK-CAR001 | March 2014 | December 2018 | December 2019 | March 7, 2014 | March 11, 2014 |
|
||
110 | NCT02159755 | Active, not recruiting | Ibrutinib and Palbociclib in Treating Patients With Previously Treated Mantle Cell Lymphoma |
|
|
Interventional | Phase 1 |
|
NIH |
|
|
28 | All | 18 Years and older (Adult, Senior) | NCT02159755 | NCI-2014-01202 1403014853 9534 K24CA201524 P30CA013696 UM1CA186704 UM1CA186712 |
May 20, 2014 | May 11, 2017 | June 10, 2014 | April 19, 2018 |
|
|||
111 | NCT03311126 | Recruiting | Bendamustine + Obinutuzumab Induction With Obinutuzumab Maintenance in Untreated Mantle Cell Lymphoma |
|
|
Interventional | Phase 2 |
|
Other / Industry / NIH |
|
|
32 | All | 18 Years and older (Adult, Senior) | NCT03311126 | UW16086 P30CA014520 2017-0609 NCI-2017-01729 |
October 19, 2017 | May 15, 2024 | May 15, 2026 | October 16, 2017 | October 25, 2017 |
|
||
112 | NCT01718691 | Completed Has Results |
Efficacy and Safety Study of SyB L-0501 in Combination With Rituximab in Patients With Untreated, Low-grade B Cell Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma |
|
|
Interventional | Phase 2 |
|
Industry |
|
|
70 | All | 20 Years to 79 Years (Adult, Senior) | NCT01718691 | 2011002 | November 2011 | November 2013 | November 2013 | October 31, 2012 | April 27, 2016 | April 27, 2016 |
|
|
113 | NCT00109967 | Completed Has Results |
CCI-779 and Rituximab in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma |
|
|
Interventional | Phase 2 |
|
NIH |
|
|
71 | All | 18 Years and older (Adult, Senior) | NCT00109967 | NCI-2009-00644 N038H U10CA025224 CDR0000425334 |
May 2005 | September 2009 | March 2012 | May 4, 2005 | April 17, 2014 | January 22, 2014 |
|
|
114 | NCT03425591 | Recruiting | A Study of Ibrutinib in the Treatment of Chronic Lymphocytic Leukemia and Mantle-cell Lymphoma in Routine Clinical Practice |
|
|
Observational |
|
Industry |
|
|
500 | All | 18 Years and older (Adult, Senior) | NCT03425591 | CR107363 54179060CAN4001 |
FIRE | May 11, 2016 | May 22, 2022 | May 22, 2022 | February 7, 2018 | March 8, 2018 |
|
||
115 | NCT02242097 | Recruiting | Ibrutinib After Intensive Induction in Treating Patients With Previously Untreated Mantle Cell Lymphoma |
|
|
Interventional | Phase 2 |
|
Other / Industry / NIH |
|
|
36 | All | 18 Years and older (Adult, Senior) | NCT02242097 | NU 14H06 NCI-2014-01777 PCI-32765MCL2003 STU00098385 P30CA060553 |
January 2015 | June 2018 | January 2019 | September 16, 2014 | March 1, 2018 |
|
||
116 | NCT01460602 | Terminated | Velcade, Nipent, Rituxan (VNR) in Subjects With Relapsed Follicular, Marginal Zone, and Mantle Cell Lymphoma |
|
|
Interventional | Phase 1 Phase 2 |
|
Other / Industry |
|
|
30 | All | 18 Years to 85 Years (Adult, Senior) | NCT01460602 | X05266 | May 2010 | October 2014 | October 2014 | October 27, 2011 | October 27, 2011 |
|
||
117 | NCT00656084 | Completed Has Results |
Ph2 Gem/Nov/Rituxan Rel/Ref MantleCell |
|
|
Interventional | Phase 2 |
|
Industry |
|
|
16 | All | 18 Years and older (Adult, Senior) | NCT00656084 | 04-026 | December 2004 | January 2007 | January 2008 | April 10, 2008 | November 3, 2016 | November 3, 2016 | ||
118 | NCT00871546 | Terminated | SCH 727965 in Patients With Mantle Cell Lymphoma or B-Cell Chronic Lymphocytic Leukemia (Study P04715) |
|
|
Interventional | Phase 2 |
|
Industry |
|
|
8 | All | 18 Years and older (Adult, Senior) | NCT00871546 | P04715 | March 2009 | December 2010 | December 2010 | March 30, 2009 | August 7, 2015 | |||
119 | NCT01527149 | Active, not recruiting | Ofatumumab in Combination With Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine Sulfate, and Dexamethasone Alternating With Ofatumumab in Combination With Cytarabine and Methotrexate in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma |
|
|
Interventional | Phase 2 |
|
Other / NIH |
|
|
37 | All | 18 Years to 70 Years (Adult, Senior) | NCT01527149 | I 201611 NCI-2011-03562 P30CA016056 |
December 6, 2011 | October 5, 2020 | October 5, 2021 | February 6, 2012 | January 29, 2018 |
|
||
120 | NCT00433537 | Completed Has Results |
Combination Chemotherapy and Rituximab in Treating Patients With Untreated Mantle Cell Lymphoma |
|
|
Interventional | Phase 2 |
|
NIH |
|
|
77 | All | 18 Years and older (Adult, Senior) | NCT00433537 | NCI-2012-02966 E1405 U10CA021115 |
May 2007 | June 2013 | June 2013 | February 12, 2007 | October 30, 2014 | October 30, 2014 |
|
|
121 | NCT02489123 | Recruiting | Enzalutamide in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma |
|
|
Interventional | Not Applicable |
|
Other / NIH |
|
|
20 | All | 18 Years and older (Adult, Senior) | NCT02489123 | 9340 NCI-2015-00947 P30CA015704 |
August 11, 2015 | July 1, 2023 | July 2, 2015 | March 29, 2018 |
|
|||
122 | NCT00003502 | Withdrawn | Antineoplaston Therapy in Treating Patients With Mantle Cell Lymphoma |
|
|
Interventional | Phase 2 |
|
Other |
|
0 | All | 18 Years and older (Adult, Senior) | NCT00003502 | BC-LY-9 CDR0000066542 |
January 27, 2003 | July 10, 2013 |
|
||||||
123 | NCT00958256 | Completed Has Results |
Study of Bortezomib in Combination With Cyclophosphamide and Rituximab |
|
|
Interventional | Phase 2 |
|
Other / Industry |
|
|
22 | All | 18 Years to 85 Years (Adult, Senior) | NCT00958256 | 2009-0057 X05290 NCI-2009-01577 |
August 2009 | March 2014 | March 2014 | August 13, 2009 | April 13, 2015 | April 13, 2015 |
|
|
124 | NCT00081874 | Completed | RAD001 in Relapsed or Refractory AML, ALL, CML in Blastic-Phase, Agnogenic Myeloid Metaplasia, CLL, T-Cell Leukemia, or Mantle Cell Lymphoma |
|
|
Interventional | Phase 1 Phase 2 |
|
Other / Industry |
|
|
29 | All | Child, Adult, Senior | NCT00081874 | 2003-0948 | April 2004 | September 2006 | September 2006 | April 27, 2004 | March 21, 2012 |
|
||
125 | NCT02413489 | Terminated | An Efficacy and Safety Proof of Concept Study of Daratumumab in Relapsed/Refractory Mantle Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma |
|
|
Interventional | Phase 2 |
|
Industry |
|
|
42 | All | 18 Years and older (Adult, Senior) | NCT02413489 | CR106660 54767414LYM2001 2014-005299-26 |
September 2, 2015 | June 1, 2017 | June 1, 2017 | April 10, 2015 | July 2, 2017 |
|
||
126 | NCT01267812 | Active, not recruiting | Bortezomib and Rituximab in Treating Patients With Mantle Cell Lymphoma Who Have Previously Undergone Stem Cell Transplantation |
|
|
Interventional | Phase 2 |
|
Other / NIH |
|
|
36 | All | 19 Years and older (Adult, Senior) | NCT01267812 | 10137 NCI-2010-02343 |
August 26, 2011 | July 2018 | July 2018 | December 29, 2010 | March 7, 2018 |
|
||
127 | NCT03229382 | Not yet recruiting | Evaluation of Efficacy and Safety of Obinutuzumab Preemptive Treatment at the Time of the Molecular Relapse After First Line Immunochemotherapy With Autologous Stem Cell |
|
|
Interventional | Phase 2 |
|
Other / Industry |
|
|
60 | All | 18 Years to 65 Years (Adult) | NCT03229382 | ML29157 2015-005439-41 |
OPERA PLRG-10 | July 2017 | July 2023 | November 2024 | July 25, 2017 | July 31, 2017 |
|
|
128 | NCT02419560 | Recruiting | Optimal Dose Finding Study ABT-199 and Ibrutinib in MCL |
|
|
Interventional | Phase 1 |
|
Other / Industry |
|
|
28 | All | 18 Years and older (Adult, Senior) | NCT02419560 | 17983 ABT199-MCL-UVA-001 |
April 2015 | August 2018 | December 2018 | April 17, 2015 | October 26, 2017 |
|
||
129 | NCT00261612 | Unknown † | Bortezomib, Rituximab and Dexamethasone (BORID) for Relapsed/Refractory Mantle Cell Lymphoma |
|
|
Interventional | Phase 2 |
|
Other |
|
|
16 | All | 19 Years to 75 Years (Adult, Senior) | NCT00261612 | 2004-002150-64 MCL 03 |
January 2005 | January 2007 | December 5, 2005 | October 18, 2006 |
|
|||
130 | NCT00921414 | Completed | Mantel Cell Lymphoma Efficacy of Rituximab Maintenance |
|
|
Interventional | Phase 3 |
|
Other |
|
|
299 | All | 18 Years to 65 Years (Adult) | NCT00921414 | Manteau 2007 SJ "LYMA" | September 2008 | September 2008 | February 2017 | June 16, 2009 | February 15, 2017 |
|
||
131 | NCT00720447 | Unknown † | Donor Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma |
|
|
Interventional | Phase 2 |
|
Other |
|
|
25 | All | 18 Years and older (Adult, Senior) | NCT00720447 | UCL-BRD-07-137 CDR0000597903 EUDRACT 2007-003081-18 |
November 2008 | November 2010 | July 22, 2008 | August 2, 2013 | ||||
132 | NCT00377052 | Completed | Bortezomib and Gemcitabine in Treating Patients With Relapsed Mantle Cell Lymphoma |
|
|
Interventional | Phase 2 |
|
Other |
|
|
29 | All | 18 Years and older (Adult, Senior) | NCT00377052 | I172 CAN-NCIC-IND172 ORTHO-CAN-NCIC-IND172 CDR0000493021 |
June 2006 | November 2009 | June 2011 | September 15, 2006 | June 22, 2011 |
|
||
133 | NCT00513955 | Completed | Combination Chemotherapy With or Without Bortezomib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma |
|
|
Interventional | Phase 2 |
|
Other |
|
|
50 | All | 18 Years and older (Adult, Senior) | NCT00513955 | CDR0000559820 NCRN-Ply-26s EU-20747 ISRCTN200600609024 |
June 2006 | October 2014 | October 2014 | August 9, 2007 | November 5, 2014 |
|
||
134 | NCT00209209 | Active, not recruiting | Induction Chemotherapy (R-CHOP Vs. R-FC) Followed by Interferon Maintenance Versus Rituximab Maintenance in MCL |
|
|
Interventional | Phase 3 |
|
Other |
|
|
570 | All | 60 Years and older (Adult, Senior) | NCT00209209 | MCL2004-1 | MCLelderly | January 14, 2004 | December 2018 | December 2018 | September 21, 2005 | March 7, 2017 |
|
|
135 | NCT01456351 | Completed | Bendamustine Plus Rituximab Versus Fludarabine Plus Rituximab |
|
|
Interventional | Phase 3 |
|
Other |
|
|
230 | All | 18 Years and older (Adult, Senior) | NCT01456351 | NHL 2-2003 | September 2003 | August 2010 | December 2010 | October 20, 2011 | February 12, 2013 |
|
||
136 | NCT00737529 | Completed Has Results |
A Study to Determine the Efficacy and Safety of Lenalidomide in Patients With Mantle Cell NHL Who Have Relapsed or Progressed After Treatment With Bortezomib or Are Refractory to Bortezomib. The "EMERGE" Trial |
|
|
Interventional | Phase 2 |
|
Industry |
|
|
134 | All | 18 Years and older (Adult, Senior) | NCT00737529 | CC-5013-MCL-001 | EMERGE | December 22, 2008 | October 15, 2012 | November 8, 2017 | August 19, 2008 | December 5, 2017 | September 9, 2013 |
|
137 | NCT00490529 | Completed | Phase 1-2 of a CpG-Activated Whole Cell Vaccine Followed by Autologous Immunotransplant for MCL |
|
|
Interventional | Phase 2 |
|
Other / NIH |
|
|
61 | All | 21 Years to 70 Years (Adult, Senior) | NCT00490529 | LYMNHL0040-BMT212 IRB-05089 96940 |
August 2009 | December 14, 2017 | December 14, 2017 | June 22, 2007 | January 23, 2018 |
|
||
138 | NCT02603445 | Active, not recruiting | Study of Safety and Efficacy of BCL201 and Idelalisib in Patients With FL and MCL |
|
|
Interventional | Phase 1 |
|
Industry |
|
|
20 | All | 18 Years and older (Adult, Senior) | NCT02603445 | CBCL201X2102C | November 16, 2015 | June 29, 2018 | June 29, 2018 | November 11, 2015 | April 23, 2018 |
|
||
139 | NCT00700258 | Recruiting | Registry For Temsirolimus, Sunitinib, And Axitinib Treated Patients With Metastatic Renal Cell Carcinoma (mRCC), Mantle Cell Lymphoma (MCL), And Gastro-Intestinal Stroma Tumor (GIST) [STAR-TOR] |
|
|
Observational |
|
Industry |
|
|
1600 | All | 18 Years to 99 Years (Adult, Senior) | NCT00700258 | 3066K1-4407 B1771009 |
STAR-TOR | January 2013 | December 2023 | December 2023 | June 18, 2008 | January 9, 2018 |
|
||
140 | NCT00003541 | Completed | Combination Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Mantle Cell Lymphoma |
|
|
Interventional | Phase 1 Phase 2 |
|
Other / NIH |
|
24 | All | 18 Years and older (Adult, Senior) | NCT00003541 | 98-045 CDR0000066595 NCI-H98-0021 |
June 1998 | July 2006 | July 2006 | January 23, 2004 | June 24, 2013 |
|
|||
141 | NCT00151281 | Completed Has Results |
Phase II Study of RT-PEPC in Relapsed Mantle Cell Lymphoma |
|
|
Interventional | Phase 2 |
|
Other |
|
|
25 | All | 18 Years and older (Adult, Senior) | NCT00151281 | 047080073974 | November 2004 | December 2009 | April 7, 2011 | September 8, 2005 | September 12, 2017 | September 12, 2017 |
|
|
142 | NCT02267590 | Unknown † | Tissue Collection for Biomarkers Determining Resistance to Ibrutinib |
|
Observational |
|
Other |
|
|
120 | All | Child, Adult, Senior | NCT02267590 | CCR4187 | CLARITY | October 2014 | October 2016 | October 2016 | October 17, 2014 | October 17, 2014 |
|
|||
143 | NCT00016887 | Unknown † | Chemotherapy Followed by Radiation Therapy and Peripheral Stem Cell Transplant Compared With Chemotherapy Plus Interferon Alfa in Treating Patients With Stage III or Stage IV Mantle Cell Lymphoma |
|
|
Interventional | Phase 3 |
|
Other |
|
All | 18 Years to 65 Years (Adult) | NCT00016887 | CDR0000068609 GER-LGLSG-INTERGROUP-20995 EORTC-20995 GELA-INTERGROUP-20995 GISL-INTERGROUP-20995 |
December 2000 | January 27, 2003 | September 17, 2013 |
|
||||||
144 | NCT01170052 | Withdrawn | Bendamustine and Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Non-Hodgkin's Lymphoma (NHL) |
|
|
Interventional | Phase 1 Phase 2 |
|
Other / Industry |
|
|
20 | All | 18 Years and older (Adult, Senior) | NCT01170052 | EudraCT-No.: 2009-014844-13 | May 2010 | April 2012 | April 2014 | July 27, 2010 | March 16, 2011 |
|
||
145 | NCT00117988 | Completed Has Results |
17-AAG in Treating Patients With Relapsed or Refractory Anaplastic Large Cell Lymphoma, Mantle Cell Lymphoma, or Hodgkin's Lymphoma |
|
|
Interventional | Phase 2 |
|
NIH |
|
|
22 | All | 16 Years and older (Child, Adult, Senior) | NCT00117988 | NCI-2009-00101 CDR0000433593 2004-0792 6936 P30CA016672 R21CA117070 |
February 2005 | April 2010 | April 2010 | July 11, 2005 | May 30, 2014 | May 30, 2011 |
|
|
146 | NCT00004231 | Completed | Combination Chemotherapy, Bone Marrow or Peripheral Stem Cell Transplantation, and/or Biological Therapy in Treating Patients With Stage III or Stage IV Mantle Cell Lymphoma |
|
|
Interventional | Phase 2 |
|
Other / NIH |
|
All | 18 Years and older (Adult, Senior) | NCT00004231 | NU 96H3 NU-96H3 NCI-G99-1659 |
October 1999 | August 2006 | August 2006 | January 27, 2003 | June 6, 2012 |
|
||||
147 | NCT03235544 | Recruiting | A Study of INCB050465 in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a BTK Inhibitor (CITADEL-205) |
|
|
Interventional | Phase 2 |
|
Industry |
|
|
120 | All | 18 Years and older (Adult, Senior) | NCT03235544 | INCB 50465-205 (CITADEL-205) | October 5, 2017 | July 2020 | May 2021 | August 1, 2017 | March 27, 2018 |
|
||
148 | NCT00703664 | Completed | Bortezomib and Vorinostat in Treating Patients With Recurrent Mantle Cell Lymphoma or Recurrent and/or Refractory Diffuse Large B-Cell Lymphoma |
|
|
Interventional | Phase 2 |
|
NIH |
|
|
65 | All | 18 Years and older (Adult, Senior) | NCT00703664 | NCI-2009-00275 CDR0000598308 MCC-8064 8064 N01CM00071 N01CM00100 N01CM62201 N01CM62204 N01CM62208 P30CA076292 |
July 9, 2008 | December 1, 2017 | June 23, 2008 | March 27, 2018 |
|
|||
149 | NCT01397591 | Terminated Has Results |
Ofatumumab and Bortezomib in Subjects With Relapsed CD20+Diffuse Large B Cell, Follicular, or Mantle Cell Lymphoma |
|
|
Interventional | Phase 2 |
|
Other / NIH / Industry |
|
|
3 | All | 18 Years and older (Adult, Senior) | NCT01397591 | IRB00007042 NCI-2011-01032 OFT113735 |
October 2011 | May 2013 | July 2013 | July 19, 2011 | July 30, 2014 | July 30, 2014 |
|
|
150 | NCT00740415 | Completed | Rituximab, Bortezomib,Bendamustine , Dexamethasone, Patients With Mantle Cell Lymphoma |
|
|
Interventional | Phase 2 |
|
Other / Industry |
|
|
39 | All | 65 Years to 80 Years (Adult, Senior) | NCT00740415 | CDR0000589544 -MANTEAU-2010-SA |
ManteauRiBVD | June 2007 | May 2011 | August 2015 | August 25, 2008 | March 16, 2016 |
|
† Study has passed its completion date and status has not been verified in more than two years.